Lithium preparations have been successfully used to treat bipolar disorder (BD), and remain the best established long-term treatment for the disorder. In fact, lithium is a cornerstone of treatment to minimize the risk of recurrences and improve inter-episodic symptomatology. We reviewed the available evidence for the use of lithium in the treatment of BD, including its efficacy, limitations, and potential benefits also in consideration of the different formulations available. We also overviewed salient comparative aspects regarding the long-term alternative use of anticonvulsants, antidepressants, and antipsychotics in BD patients. The available evidence indicates that BD patients should be treated primarily with lithium, combined in some cases with antipsychotics especially in acute treatments, and sometimes, because of intolerance or inefficacy of lithium, with anticonvulsants. The use of adjunctive antidepressants should be limited to episodes of breakthrough depression. Lithium should be offered to the majority of BD patients as initial treatment especially when suicide ideation or behavior is present with adequate information about its long-term benefits and its potential side effects. Many patients can tolerate lithium without concomitant use of antidepressants, which may worsen the course of the illness or antipsychotics, which may cause severe long-term side effects.

Treatment of Bipolar Disorder in a Lifetime Perspective. Is Lithium Still the Best Choice? / Sani, Gabriele; Perugi, Giulio; Tondo, Leonardo. - In: CLINICAL DRUG INVESTIGATION. - ISSN 1173-2563. - ELETTRONICO. - 37:8(2017), pp. 713-727. [10.1007/s40261-017-0531-2]

Treatment of Bipolar Disorder in a Lifetime Perspective. Is Lithium Still the Best Choice?

SANI, Gabriele;
2017

Abstract

Lithium preparations have been successfully used to treat bipolar disorder (BD), and remain the best established long-term treatment for the disorder. In fact, lithium is a cornerstone of treatment to minimize the risk of recurrences and improve inter-episodic symptomatology. We reviewed the available evidence for the use of lithium in the treatment of BD, including its efficacy, limitations, and potential benefits also in consideration of the different formulations available. We also overviewed salient comparative aspects regarding the long-term alternative use of anticonvulsants, antidepressants, and antipsychotics in BD patients. The available evidence indicates that BD patients should be treated primarily with lithium, combined in some cases with antipsychotics especially in acute treatments, and sometimes, because of intolerance or inefficacy of lithium, with anticonvulsants. The use of adjunctive antidepressants should be limited to episodes of breakthrough depression. Lithium should be offered to the majority of BD patients as initial treatment especially when suicide ideation or behavior is present with adequate information about its long-term benefits and its potential side effects. Many patients can tolerate lithium without concomitant use of antidepressants, which may worsen the course of the illness or antipsychotics, which may cause severe long-term side effects.
2017
pharmacology (medical); long-term treatment; manic-depressive illness; placebo-controlled trial; double-blind; i-disorder; maintenance treatment; mood disorders; suicide risk; pharmacological-treatment; prophylactic efficacy
01 Pubblicazione su rivista::01a Articolo in rivista
Treatment of Bipolar Disorder in a Lifetime Perspective. Is Lithium Still the Best Choice? / Sani, Gabriele; Perugi, Giulio; Tondo, Leonardo. - In: CLINICAL DRUG INVESTIGATION. - ISSN 1173-2563. - ELETTRONICO. - 37:8(2017), pp. 713-727. [10.1007/s40261-017-0531-2]
File allegati a questo prodotto
File Dimensione Formato  
Sani_Treatment_2017.pdf

solo gestori archivio

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 411.87 kB
Formato Adobe PDF
411.87 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/961748
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 47
  • ???jsp.display-item.citation.isi??? 42
social impact